compound 14d

Compound 14d is a novel 8-substituted theophylline (1,3-dimethylxanthine) hybrid developed as a dual-acting therapeutic candidate for the management of asthma. It functions as a potent inhibitor of phosphodiesterase 4B (PDE-4B), an enzyme critical to airway inflammation and bronchoconstriction. In preclinical studies, compound 14d demonstrated significant bronchodilatory activity in guinea pig models, surpassing the efficacy of theophylline. Additionally, it exhibits antibacterial properties against Gram-positive and Gram-negative bacterial strains commonly associated with asthma pathogenesis. Molecular dynamics simulations indicate that the compound forms a stable and strong binding interaction within the PDE-4B active site, supporting its potential as an anti-inflammatory and bronchodilatory agent.